Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
暂无分享,去创建一个
F. Baas | R. Kleemann | C. van Kooten | K. Fluiter | N. Keijzer | B. Morgan | A. Kiliaan | L. Verschuren | W. van Duyvenvoorde | A. Menke | M. Morrison | S. W. van der Kooij | F. Seidel | Johnathan J Winter | Nikki van Trigt | Timothy R. Hughes | T. Hughes | Timothy R Hughes
[1] Shelly C. Lu,et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles , 2022, Hepatology (Baltimore, Md.).
[2] Shelly C. Lu,et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles , 2022, Hepatology.
[3] T. Hendrikx,et al. Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis , 2022, Frontiers in Cardiovascular Medicine.
[4] Arturo Santos,et al. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases , 2021, International journal of molecular sciences.
[5] Xiaofeng Yang,et al. Complement Inhibition Targeted to Injury Specific Neoepitopes Attenuates Atherogenesis in Mice , 2021, Frontiers in Cardiovascular Medicine.
[6] S. Friedman,et al. Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies , 2021, Journal of internal medicine.
[7] R. Kleemann,et al. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. , 2021, Metabolism: clinical and experimental.
[8] A. B. Storsve,et al. Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms , 2021, Nutrients.
[9] Sahmin Lee,et al. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases , 2021, International journal of molecular sciences.
[10] R. Kleemann,et al. Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine , 2021, Frontiers in Endocrinology.
[11] V. Saini,et al. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis , 2020, Oxidative medicine and cellular longevity.
[12] R. Kleemann,et al. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology , 2020, Cells.
[13] Jiao Guo,et al. The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise , 2020, Hepatology International.
[14] B. Stockinger,et al. Characterizing the original anti‐C5 function‐blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5 , 2020, Immunology.
[15] V. Fuster,et al. Complement C5 Protein as a Marker of Subclinical Atherosclerosis. , 2020, Journal of the American College of Cardiology.
[16] H. Malhi,et al. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview , 2020, Hepatology communications.
[17] R. Kleemann,et al. Combined Treatment with L-Carnitine and Nicotinamide Riboside Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis , 2019, International journal of molecular sciences.
[18] A. Murphy,et al. Monocytes, Macrophages, and Metabolic Disease in Atherosclerosis , 2019, Front. Pharmacol..
[19] C. Weber,et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q , 2019, Nature Medicine.
[20] G. Paragh,et al. The Impact of Obesity on the Cardiovascular System , 2018, Journal of diabetes research.
[21] R. Kleemann,et al. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice , 2018, Hepatology communications.
[22] G. Cao,et al. Complement Complex C5b-9 Levels Are Associated with the Clinical Outcomes of Acute Ischemic Stroke and Carotid Plaque Stability , 2018, Translational Stroke Research.
[23] P. Libby,et al. Atherosclerosis and inflammation: overview and updates. , 2018, Clinical science.
[24] R. Kleemann,et al. Key Inflammatory Processes in Human NASH Are Reflected in Ldlr−/−.Leiden Mice: A Translational Gene Profiling Study , 2018, Front. Physiol..
[25] A. Sanyal,et al. Preclinical models of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.
[26] R. Goldschmeding,et al. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model , 2017, Cellular and molecular gastroenterology and hepatology.
[27] T. Kooistra,et al. A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice , 2017, PloS one.
[28] L. Bavia,et al. The complement component C5 promotes liver steatosis and inflammation in murine non-alcoholic liver disease model. , 2016, Immunology letters.
[29] Yun Zhang,et al. Overexpression of complement component C5a accelerates the development of atherosclerosis in ApoE-knockout mice , 2016, Oncotarget.
[30] T. Kooistra,et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. , 2016, Atherosclerosis.
[31] Youming Li,et al. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population , 2016, Scientific Reports.
[32] Armugam P Mekala,et al. The role of complement activation in atherogenesis: the first 40 years , 2015, Immunologic Research.
[33] T. Kooistra,et al. Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined Oil , 2015, PloS one.
[34] H. Völzke,et al. Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis , 2015, Gastroenterology.
[35] Qing Zhang,et al. Association between Complement C3 and Prevalence of Fatty Liver Disease in an Adult Population: A Cross-Sectional Study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) Cohort Study , 2015, PloS one.
[36] M. Daha,et al. Functional assessment of mouse complement pathway activities and quantification of C3b/C3c/iC3b in an experimental model of mouse renal ischaemia/reperfusion injury. , 2015, Journal of immunological methods.
[37] Chang Liu,et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. , 2015, World journal of gastroenterology.
[38] R. Kleemann,et al. Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.
[39] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[40] Gongxiong Wu,et al. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. , 2014, Atherosclerosis.
[41] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[42] B. Fromenty,et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease , 2013, Hepatology.
[43] E. Feskens,et al. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study , 2013, European journal of clinical investigation.
[44] T. Hughes,et al. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation , 2013, Journal of Cell Science.
[45] L. Gan,et al. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications , 2012, Gut and liver.
[46] C. Cook,et al. The effect of complement C5a on mitochondrial functions of PC12 cells , 2011, Neuroreport.
[47] A. Zernecke,et al. Complement C5a inhibition reduces atherosclerosis in ApoE–/– mice , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[48] K. Cianflone,et al. Complement C3 and cleavage products in cardiometabolic risk. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[49] J. Wojta,et al. Complement in atherosclerosis: friend or foe? , 2011, Journal of thrombosis and haemostasis : JTH.
[50] A. Zernecke,et al. C5a Receptor Targeting in Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice , 2010, Circulation.
[51] T. Hughes,et al. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice , 2010, Molecular immunology.
[52] R. Steffensen,et al. Activation of the complement system in human nonalcoholic fatty liver disease , 2009, Hepatology.
[53] Jichun Yang,et al. Induction of MIF expression by oxidized LDL via activation of NF-kappaB in vascular smooth muscle cells. , 2009, Atherosclerosis.
[54] P. Zipfel,et al. Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.
[55] J. H. van Bockel,et al. MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease , 2009, Circulation research.
[56] D. Rader,et al. CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. , 2009, Molecular immunology.
[57] Gongxiong Wu,et al. Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex , 2009, Circulation research.
[58] J. Boyle,et al. Brief Report: Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice Lacking the Membrane-Bound Complement Regulator CD59 , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[59] A. Blom,et al. Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. , 2007, Atherosclerosis.
[60] J. Bernhagen,et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.
[61] Jörg Köhl,et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans , 2005, Nature Genetics.
[62] P. Ward,et al. Role of C5a in inflammatory responses. , 2005, Annual review of immunology.
[63] P. Libby,et al. Low-Density Lipoprotein Receptor-Deficient Mice Macrophage Migration Inhibitory Factor Deficiency Impairs Atherosclerosis in , 2022 .
[64] B. Jaber,et al. C5a delays apoptosis of human neutrophils via an extracellular signal‐regulated kinase and Bad‐mediated signalling pathway , 2004, European journal of clinical investigation.
[65] H. Rus,et al. The role of complement activation in atherosclerosis , 2004, Immunologic research.
[66] S. Verma,et al. New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.
[67] W. Leonard,et al. Cytokine and Cytokine Receptor Pleiotropy and Redundancy* , 2002, The Journal of Biological Chemistry.
[68] J. Bernhagen,et al. Expression of Macrophage Migration Inhibitory Factor in Different Stages of Human Atherosclerosis , 2002, Circulation.
[69] Y. Chao,et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. , 2001, Biochemical and biophysical research communications.
[70] R. Kinscherf,et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[71] P. Ward,et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. , 1997, The American journal of pathology.
[72] W D Wagner,et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[73] H. Rus,et al. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. , 1987, Clinical and experimental immunology.